Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth (Q39527903)
Jump to navigation
Jump to search
scientific article published on 8 June 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth |
scientific article published on 8 June 2011 |
Statements
1 reference
Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth (English)
1 reference
Jun Yan
1 reference
Bingxian Xie
1 reference
Jillian L Capodice
1 reference
Aaron E Katz
1 reference
8 June 2011
1 reference
1 reference
72
1 reference
3
1 reference
244-252
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference